Screening of pregnant women for hepatitis B virus surface antigen (HBsAg) and subsequent management, Qiandongnan prefecture, Guizhou, China, 2010

Huang, Yan; Li, Leilei; Sun, Xiaohong; Lu, Mei; Liu, Huihui; Tang, Guangpeng; Wang, Dingming; Hutin, Yvan

doi:10.1016/j.vaccine.2013.05.103

Cited by 19 publications

(21 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…China has high HBV endemicity, with a 7.18% prevalence of HBsAg . The overall HBsAg prevalence in women of childbearing age is 6.1%‐9.51% . Among HBsAg‐positive women aged 15‐39 years, 30% are HBeAg‐positive, indicating a high risk of perinatal infection …”

Section: Discussionmentioning

confidence: 99%

Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother‐to‐child transmission of hepatitis B virus

Xie

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Women with chronic hepatitis B should maintain nucleotide analogue treatment to prevent disease progression during pregnancy. The aim of this study was to prospectively evaluate the efficacy and safety of telbivudine used throughout pregnancy for preventing hepatitis B virus (HBV) mother-to-child transmission (MTCT). From January 2012 to June 2014, women who were receiving telbivudine therapy and became pregnant were enrolled in group A at 28 weeks of gestation. Pregnant women with an HBV DNA level >10 IU/mL were enrolled in either group B (telbivudine started at 28 weeks of gestation) or group C (control group without treatment). MTCT was defined as infants who were positive for serum hepatitis B surface antigen at 7 months after birth. There were 41, 179 and 177 pregnant women (397 infants) enrolled in groups A, B and C, respectively. The HBV DNA load at 28 weeks of gestation and delivery was 1.50 ± 0.62 vs 1.45 ± 0.61, 8.05 ± 0.37 vs 4.24 ± 0.89 and 7.94 ± 0.62 vs 7.86 ± 0.73 log IU/mL in groups A, B and C, respectively. The rate of MTCT in group C was 4.60%, which was significantly higher than the rates in groups A and B (0% and 0.6%, respectively) (P = .043). The difference between group A and group B was not significant. The rates of neonatal congenital abnormalities were 2.4%, 0.6% and 2.3% in groups A, B and C, respectively, and there were no significant differences (P = .140). Telbivudine used throughout pregnancy may be safe and effective for mothers and infants, but it may not enhance the efficacy of an HBV MTCT block compared with treatment starting at 28 weeks of gestation (NCT02253485).

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother‐to‐child transmission of hepatitis B virus

Xie

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…It has been reported that the carrier rate of the hepatitis B surface antigen (HBsAg) among pregnant women in China is 2% to 8%. 1,2 Nearly one million children face the risk of HBV infection each year. For babies newly born to mothers with HBsAg positivity, the current clinical position is to adopt a preventive strategy by inoculating the newborn with the HBV vaccine and hepatitis B immunoglobulin (HBIG) within 12 hours of birth.…”

Section: The Number Of Patients Infected With the Hepatitis B Virus (mentioning

confidence: 99%

“…The number of patients infected with the hepatitis B virus (HBV) in China is immense. It has been reported that the carrier rate of the hepatitis B surface antigen (HBsAg) among pregnant women in China is 2% to 8% . Nearly one million children face the risk of HBV infection each year.…”

Section: Introductionmentioning

confidence: 99%

Study of the distribution of hepatitis B immunoglobulin in pregnant mice using small‐animal imaging technology

Chen

Kong

Shi

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Background The safety and necessity of hepatitis B immunoglobulin (HBIG) in preventing the mother‐to‐child transmission of hepatitis B virus (HBV) are still controversial because of its unclear mechanism of action and the inconsistent injection programs used during gestation. Objectives This study aimed to show the dynamic transportation and distribution of HBIG in the maternal body and to provide evidence for its clinical efficacy in preventing mother‐to‐child HBV transmission. Study design Pregnant mice were injected with Cy7‐labeled mouse anti‐human monoclonal hepatitis B surface antibodies through the tail vein. In vivo imaging technology was used to observe the dynamic transportation and distribution of HBIG in the pregnant mice. Results HBIG fluorescence signals were higher in the uterus than in the liver, spleen, and kidneys. Fluorescence signals in the uterine region were obviously higher at the third trimester than at early and mid pregnancy. Conclusions HBIG is gradually deposited in the mouse placenta during pregnancy, with the phenomenon being more significant in the third trimester.

show abstract

“…Since perinatal transmission is a major route of HBV infection in endemic Asian countries or regions, administration of a TBD of the HBV vaccine (within 24 hours after delivery) is the key to preventing perinatal HBV infection. Timely birth dose plus 3‐dose series are >90% effective in preventing MTCT of HBV.…”

Section: Implementation Of the Timely Birth Dose (Tbd)mentioning

confidence: 99%

How to control highly endemic hepatitis B in Asia

Shan

Cui

Jia

2018

Liver International

View full text Add to dashboard Cite

show abstract

Screening of pregnant women for hepatitis B virus surface antigen (HBsAg) and subsequent management, Qiandongnan prefecture, Guizhou, China, 2010

Cited by 19 publications

References 7 publications

Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother‐to‐child transmission of hepatitis B virus

Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother‐to‐child transmission of hepatitis B virus

Study of the distribution of hepatitis B immunoglobulin in pregnant mice using small‐animal imaging technology

How to control highly endemic hepatitis B in Asia

Contact Info

Product

Resources

About